Europe Immunoassay Analyzers Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

Immunoassay analyzers are a core segment of the European in-vitro diagnostics (IVD) industry, used across hospital laboratories, independent reference labs, blood banks, and point-of-care settings. The Europe region represents one of the world's largest immunoassay analyzer markets, supported by universal or near-universal healthcare coverage, structured screening mandates, and high testing volumes per capita. Within the regional IVD stack, immunoassay typically accounts for a substantial share of clinical chemistry and immunodiagnostic spending. Market growth is steady rather than explosive, reflecting mature laboratory infrastructure offset by continuous test-volume expansion.

• •Market size in 2025 is approximately $11.003 billion, growing at a 5.09% CAGR.
• •Anchored by high healthcare access, centralized lab networks, and rigorous screening requirements across the EU and UK.
• •Long forecast horizons typically span 2030-2036 across multiple analyst outlooks.

A combination of demographic pressure and clinical demand is sustaining growth in Europe. Aging populations are increasing the incidence of cardiovascular disease, cancer, diabetes, and autoimmune disorders, all of which rely heavily on immunoassay-based testing. Expanded newborn screening, infectious-disease surveillance, and therapeutic drug monitoring are adding to test volumes, while hospitals continue to consolidate onto automated, high-throughput platforms to manage rising workloads with limited staff.

• •Rising chronic disease and cancer incidence driven by Europe's aging demographic profile.
• •Broader screening programs (newborn, infectious disease, oncology biomarkers) expanding routine test menus.
• •Ongoing lab automation and workforce shortages pushing adoption of high-throughput random-access analyzers.

The market is segmented by technology (chemiluminescence, ELISA, radioimmunoassay, enzyme immunoassay, and others), by product (analyzers and reagents/consumables), by application (infectious disease, oncology, endocrinology, cardiology, autoimmune, drugs of abuse, and others), and by end user (hospitals, clinical/diagnostic labs, academic and research institutes). Chemiluminescence dominates current analyzer placements, while reagents and consumables generate a recurring revenue stream that is typically larger and more stable than analyzer hardware sales. Geographically, Western European economies, particularly Germany, France, the UK, Italy, and Spain, account for the majority of revenue, with Central and Eastern Europe representing faster-growing but smaller-volume markets.

• •Chemiluminescence is the leading technology platform; ELISA remains widely used in lower-throughput settings.
• •Reagents/consumables typically outweigh analyzer hardware in total market revenue over time.
• •Germany, France, the UK, Italy, and Spain lead spending; CEE countries show above-average growth rates.

What are the recent trends and outlook?

The outlook through the early 2030s is for continued mid-single-digit growth, supported by test-menu expansion rather than dramatic unit-volume shifts. Key trends include broader adoption of fully automated, random-access chemiluminescence systems; integration of immunoassay workflows with clinical chemistry and molecular diagnostics on consolidated platforms; and tighter coupling of analyzers with laboratory information systems and middleware. Regulatory pressure under the EU IVDR (In Vitro Diagnostic Regulation) is reshaping CE marking, performance evidence requirements, and post-market surveillance across the region. Emerging growth areas include multiplexed biomarker panels for oncology and autoimmune disease, point-of-care immunoassays, and software-enabled decision support linked to analyzer data.

• •EU IVDR compliance is reshaping product approvals, labeling, and post-market performance requirements across Europe.
• •Consolidation of immunoassay, clinical chemistry, and molecular testing onto integrated platforms is accelerating in mid- and large-volume laboratories.
• •Opportunity pockets include oncology biomarkers, autoimmune panels, infectious-disease multiplexing, and point-of-care immunoassays.